The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Clinical Use of DPP-4 Inhibitors
Open accessAbstract
DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk. Their efficacy potential to lower HbA1c is in the range between 0.5 and 1.0% and their safety profile is favorable. DPP-4 inhibitors are body weight neutral and they have demonstrated cardiovascular safety. Most compounds can be used in impaired renal function. Guidelines suggest the additional use of DPP-4 inhibitors after metformin failure in patients that do not require antidiabetic therapy with proven cardiovascular benefit. Recently, DPP-4 inhibitors have increasingly replaced sulfonylureas as second line therapy after metformin failure and many metformin/DPP-4 inhibitor fixed dose combinations are available. In later stages of type 2 diabetes, DPP-4 inhibitors are also recommended in the guidelines in triple therapies with metformin and SGLT-2 inhibitors or with metformin and insulin. A treatment with DPP-4 inhibitors should be stopped when GLP-1 receptor agonists are used. DPP-4 inhibitors can be used as monotherapy when metformin is contraindicated or not tolerated. Some studies have shown value of initial metformin-DPP-4 inhibitor combination therapy in special populations. This article gives an overview on the clinical use of DPP-4 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
Palmer, S. C., Mavridis, D., Nicolucci, A., Johnson, D. W., Tonelli, M., Craig, J. C., Maggo, J., Gray, V., De Berardis, G., Ruospo, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.9400 · Cited by 420
Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60691-6 · Cited by 343
Self-citationNabeno, M., Akahoshi, F., Kishida, H., Miyaguchi, I., Tanaka, Y., Ishii, S., & Kadowaki, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.010 · Cited by 310
DeFronzo, R. A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Care · doi:10.2337/dc14-2364 · Cited by 296
Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., & Iqbal, N. (2015) · Diabetes Care · doi:10.2337/dc14-1142 · Cited by 290
Gerich, J. E. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.447 · Cited by 222
McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0103 · Cited by 217
DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
Monami, M., Lamanna, C., Desideri, C. M., & Mannucci, E. (2012) · Advances in Therapy · doi:10.1007/s12325-011-0088-z · Cited by 217
Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115570301 · Cited by 212 · cited 1×
“Glimepiride in Type 2 Diabetes) with linagliptin comparing linagliptin treatment as add on to metformin directly with a therapy with the sulfonylurea glimepiride will bring results later in 2019 and may give additional insights into the association and mechanisms linking hypoglycaemic- with cardiovascular events (24,…”
BackgroundSeck, T., Nauck, M., Sheng, D., Sunga, S., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & for the Sitagliptin Study 024 Group (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02353.x · Cited by 208
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205
Matthews, D. R., Dejager, S., Ahren, B., Fonseca, V., Ferrannini, E., Couturier, A., Foley, J. E., & Zinman, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01233.x · Cited by 199
Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
Lewin, A., DeFronzo, R. A., Patel, S., Liu, D., Kaste, R., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Care · doi:10.2337/dc14-2365 · Cited by 188
Arechavaleta, R., Seck, T., Chen, Y., Krobot, K. J., O’Neill, E. A., Duran, L., Kaufman, K. D., Williams‐Herman, D., & Goldstein, B. J. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01334.x · Cited by 169
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, P. G., Davidson, J. A., Nicolau, J. C., Corbalan, R., Hirshberg, B., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1850 · Cited by 163
Mathieu, C., Ranetti, A.-E., Li, D., Ekholm, E., Cook, W., Hirshberg, B., Chen, H., Hansen, L., & Iqbal, N. (2015) · Diabetes Care · doi:10.2337/dc15-0779 · Cited by 154
White, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.004 · Cited by 152
FILOZOF, C. M., & Gautier, J. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02938.x · Cited by 150
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Karagiannis, T., Boura, P., & Τσάπας, Α. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614523031 · Cited by 146
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
Engel, S. S., Williams‐Herman, D., Golm, G. T., Clay, R. J., Machotka, S. V., Kaufman, K. D., & Goldstein, B. J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02382.x · Cited by 143
Green, J. B., Bethel, M. A., Paul, S. K., Ring, A., Kaufman, K. D., Shapiro, D. R., Califf, R. M., & Holman, R. R. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.09.003 · Cited by 141
The safety of gliptins : updated data in 2018
Scheen, A. J. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1444027 · Cited by 138
Deacon, C. F., & Holst, J. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.824966 · Cited by 137
Tkáč, I., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dc15-1707 · Cited by 120
Patel, B., & Ghate, M. D. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.12.038 · Cited by 117
Scheen, A. J. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1215427 · Cited by 110
Chen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12455 · Cited by 103
Risk of pancreatitis in patients treated with incretin-based therapies
Meier, J. J., & Nauck, M. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3231-y · Cited by 101
Monami, M., Vitale, V., Ambrosio, M. L., Bartoli, N., Toffanello, G., Ragghianti, B., Monami, F., Marchionni, N., & Mannucci, E. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0045-5 · Cited by 99
Vardarli, I., Arndt, E., Deacon, C. F., Holst, J. J., & Nauck, M. A. (2013) · Diabetes · doi:10.2337/db13-0805 · Cited by 98
Pinto, L. C. F., Rados, D. R. V., Barkan, S. S., Leitão, C. B., & Gross, J. L. (2018) · Scientific Reports · doi:10.1038/s41598-017-19055-6 · Cited by 96
Prato, S. D., Camisasca, R., Wilson, C., & Fleck, P. R. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12377 · Cited by 94
Matthaei, S., Catrinoiu, D., Celiñski, A., Ekholm, E., Cook, W., Hirshberg, B., Chen, H., Iqbal, N., & Hansen, L. (2015) · Diabetes Care · doi:10.2337/dc15-0811 · Cited by 91
Göke, B., Gallwitz, B., Eriksson, J. G., Hellqvist, Å., & Gause‐Nilsson, I. A. M. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12119 · Cited by 90
Self-citationRosenstock, J., Perkovic, V., Alexander, J. H., Cooper, M. E., Marx, N., Pencina, M. J., Toto, R. D., Wanner, C., Zinman, B., Baanstra, D., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0682-3 · Cited by 88
Tomović, K., Lazarević, J., Kocic, G. M., Deljanin-Ilić, M., Anderluh, M., & Šmelcerović, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21513 · Cited by 88
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Sesti, G., Avogaro, A., Belcastro, S., Bonora, B. M., Croci, M., Daniele, G., Dauriz, M., Dotta, F., Formichi, C., Frontoni, S., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-018-1271-3 · Cited by 88
Fonseca, V. A., Baron, M. A., Shao, Q., & Dejager, S. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2008-1058090 · Cited by 81
Xiao, C., Dash, S., Morgantini, C., Patterson, B. W., & Lewis, G. F. (2014) · Diabetes · doi:10.2337/db13-1654 · Cited by 76
Abbas, A. S., Dehbi, H., & Ray, K. K. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12595 · Cited by 62
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Kim, S., Yoo, J.-H., Lee, W. J., & Park, C. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.5.339 · Cited by 62
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Bailey, C. J., & Marx, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13492 · Cited by 56
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C., Steg, P. G., Davidson, J. A., Öhman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 52
Nauck, M. A., Kahle, M., Baranov, O., Deacon, C. F., & Holst, J. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12802 · Cited by 44
Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes
Bianchi, C., Daniele, G., Dardano, A., Miccoli, R., & Prato, S. D. (2017) · Drugs · doi:10.1007/s40265-017-0694-4 · Cited by 43
Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
Almagthali, A., Alkhaldi, E. H., Alzahrani, A. S., Alghamdi, A. K., Alghamdi, W. Y., & Kabel, A. M. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.08.012 · Cited by 41
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy
Gallwitz, B. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.576667 · Cited by 36
Self-citationSafety of antidiabetes medications: An update
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.125 · Cited by 33
Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs
Gore, M. O., & McGuire, D. K. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0038-4 · Cited by 30
Prato, S. D., Rosenstock, J., García‐Sánchez, R., Iqbal, N., Hansen, L., JOHNSSON, E. K., Chen, H., & Mathieu, C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13258 · Cited by 28
Novel Therapeutic Approaches in Diabetes
Gallwitz, B. (2016) · Endocrine development · doi:10.1159/000439372 · Cited by 27
Self-citationWang, X., Li, X., Qie, S., Zheng, Y., Liu, Y., & Liu, G. (2018) · Medicine · doi:10.1097/md.0000000000011946 · Cited by 16
Goldenberg, R. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.10.016 · Cited by 15
Gallwitz, B. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s67076 · Cited by 9
Self-citationA safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes
Gallwitz, B. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1382471 · Cited by 7
Self-citationStudying Pancreatic Risks Caused by Incretin-Based Therapies
Nauck, M. A., & Meier, J. J. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814532874 · Cited by 4
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Self-citationAdherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
Metadata
- Authors
- Gallwitz, B.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-06-19
- Volume
- 10
- Pages
- 389-389
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2949974532
- Cited by
- 374
- References
- 80
- FWCI
- 26.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.